Key facts
- This page summarizes Rene Sindlev's Form 4 filing for Enochian Biosciences Inc (RENB).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 22 Dec 2021, 10:30.
Rene Sindlev - 28 Jul 2021 Form 4 Insider Report for Enochian Biosciences Inc (RENB)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- RENB
- Reported as of
- 28 Jul 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 22 Dec 2021, 10:30:43 UTC
- Next SEC filing
- 04 Jan 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Rene Sindlev
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Rene Sindlev filed Form 4 for Enochian Biosciences Inc (RENB) on 22 Dec 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RENB
transaction
Derivative
Option to purchase shares of common stock
Award
- Transaction value
- $0
- Shares
- +9,036
- Change %
- Price
- $0.000000
- Shares after
- 9,036
- Date
- 28 Jul 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 9,036
- Exercise price
- $4.98
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
On July 28, 2021, Mr. Sindlev was granted an option to purchase 9,036 shares of the issuer's common stock, fully vesting on July 28, 2022.